ライフサイエンスコーパス: sedatives

1 ve usual care (propofol, midazolam, or other sedatives).

2 ICU and administered with analgesics and/or sedatives.

3 nction, severity of illness, and exposure to sedatives.

4 chanical ventilation and requiring high-dose sedatives.

5 e mechanically ventilated and were receiving sedatives.

6 ounding, with the exception of hypnotics and sedatives.

7 sive care unit after stopping treatment with sedatives.

8 following loss of consciousness or receiving sedatives.

9 ine vasopressor infusions, but unaffected by sedatives.

10 to find non-benzodiazepine-based alternative sedatives.

11 people who find it hard to get to sleep take sedatives.

12 a reduces the metabolism of commonly used IV sedatives.

13 nes suggest minimizing dosage of opioids and sedatives.

14 d clinical outcomes associated with specific sedatives.

15 be unintentionally induced by heavy doses of sedatives.

16 , among individuals prescribed hypnotics and sedatives 0-1 year before diagnosis: odds ratio [OR], 6.

17 pplemental narcotics (5 mg of oxycodone) and sedatives (1 mg lorezapam), and one patient became apnei

18 s 1119 individuals [7.7%]) and hypnotics and sedatives (1609 individuals [12.2%] vs 1510 individuals

19 ed recommendations relating to: 1) choice of sedatives, 2) sedation administration, 3) personnel resp

20 ics, 3) antidepressants, 4) street drugs, 5) sedatives, 6) poisoning (carbon monoxide, arsenic, or cy

21 Daily interruption of sedatives alleviates these problems, but the impact of t

22 rug events reported to occur with the use of sedatives, analgesics, and antipsychotics in the intensi

23 of life-sustaining treatment and the use of sedatives, analgesics, and nonpharmacologic approaches t

24 propofol alone or in combination with other sedatives/analgesics has become popular for procedural s

25 The mean dose of sedatives and analgesics administered nearly doubled as

26 How critical care practitioners prescribe sedatives and analgesics and, perhaps more broadly, how

27 An evidence-based approach to administering sedatives and analgesics is necessary to optimize short-

28 ill patients receive significant amounts of sedatives and analgesics that increase their risk of dev

29 Critically ill patients are prescribed sedatives and analgesics to decrease pain and anxiety, i

30 o eye opening at 72 hours after cessation of sedatives and analgesics) occurred in 14 patients (8.9%)

31 of sedation and analgesia and total doses of sedatives and analgesics.

32 documented the advantages of pharmacological sedatives and anesthetics for use in bronchoscopy.

33 Despite the common use of sedatives and anesthetics in the acute phase of TBI mana

34 of GABA(A) receptor activity and are potent sedatives and anesthetics.

35 The use of sedatives and antibiotics may be required to be changed

36 mmonly used ICU medications, especially some sedatives and anticholinergic medications, and keeping p

37 after an intentional overdose of concomitant sedatives and antidepressants) and one attributable to l

38 Active compounds included sedatives and antipsychotic, antidepressant, and antisei

39 ely, compared with 3.6 (95% CI, 3.2-4.1) for sedatives and anxiolytics, 2.9 (95% CI, 2.3-3.5) for sti

40 idepressants, antipsychotics, lithium salts, sedatives and anxiolytics, and stimulants.

41 Sedatives and anxiolytics, antidepressants, antipsychoti

42 Currently used PAMs include benzodiazepine sedatives and anxiolytics, barbiturates, endogenous and

43 As an alternative to high-dose sedatives and controlled mechanical ventilation, pharmac

44 ngton, Minnesota, USA) and novel 'soft-drug' sedatives and hypnotics (e.g. CNS-7259X and TD-4756) as

45 ntrolling for age, diagnosis status, gender, sedatives and hypnotics use, and hypertension.

46 bilitation in routine care, including use of sedatives and lack of awareness of post-ICU cognitive im

47 The use of sedatives and neuromuscular blocking agents in the ICU i

48 daily dose, and route of administration for sedatives and neuromuscular blocking agents were abstrac

49 We compared the doses and duration of sedatives and opioid analgesics in patients receiving lo

50 ociated acute respiratory distress syndrome, sedatives and opioids are commonly administered which ma

51 Sedatives and opioids use was similar in the higher and

52 Sedatives and opioids were used in >80% of the patients

53 The use of sedatives and opioids, but not NMBAs, was associated wit

54 The use of sedatives and opioids, but not the use of NMBAs, was ass

55 comorbidities, baseline cognition, doses of sedatives and opioids, stroke risk (in cognitive models)

56 outcomes included duration of stay, doses of sedatives and opioids, unintentional device removal, del

57 The later peak misuse trajectory for sedatives and tranquilisers crested at an older age (35

58 se of continuous infusions of opioids and/or sedatives and ventilator parameters (tidal volume per id

59 Sedatives and/or analgesics were administered to 47 (89%

60 ting for relevant covariates including coma, sedatives, and analgesics in patients receiving mechanic

61 e substantial for anxiolytics, hypnotics and sedatives, and antidepressants.

62 Decisions to administer opioids, sedatives, and antipsychotic medications are frequently

63 ill patients frequently receive analgesics, sedatives, and antipsychotics to optimize patient comfor

64 sedation when possible, use of short acting sedatives, and avoidance of benzodiazepines.

65 ressive effects associated with antibiotics, sedatives, and catecholamines amplify sepsis-associated

66 and for use of antidepressants, anxiolytics, sedatives, and hypnotics, and was consistent across age

67 armacologic treatments including analgesics, sedatives, and neuromuscular blockers.

68 The use and effectiveness of analgesics, sedatives, and NMJBs, as well as cost and outcomes, were

69 gical ocular complication rates, use of oral sedatives, and reported reasons to perform the surgery i

70 prescription drug use (ie, use of narcotics, sedatives, and stimulants) have been established but are

71 prescription drugs (prescription pain pills, sedatives, and tranquilliser) were the most commonly rep

72 Sedatives/anesthetics are important medical tools to fac

73 Increasingly, there is recognition that sedatives/anesthetics can modulate immune functions.

74 en together, it is important to determine if sedatives/anesthetics mitigate TLR7 function.

75 antiinfective agents, estrogens, progestins, sedatives, anticonvulsant drugs, or drugs that may form

76 he GABAA receptor are important anesthetics, sedatives, anticonvulsants, and anxiolytics.

77 ding antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, and psychostimulants, and al

78 ith a prescription for anxiolytics/hypnotics/sedatives, antidepressants, antipsychotics, or stimulant

79 s) of GABA(A)Rs such as general anesthetics, sedatives, antiepileptics, and anxiolytics.

80 cs: AOR, 4.74 [95% CI, 3.92-5.74]; hypnotics-sedatives: AOR, 3.01 [95% CI, 2.53-3.57]; and antacids:

81 cs: AOR, 6.20 [95% CI, 5.07-7.59]; hypnotics-sedatives: AOR, 4.45 [95% CI, 3.78-5.23]; antacids: AOR,

82 ys compared with intermittent lorazepam when sedatives are interrupted daily.

83 General anesthetics and sedatives are used in millions of children every year to

84 to receive higher doses of both opioids and sedatives as they get closer to death.

85 dverse events and route of administration of sedatives as well as image quality.

86 Among those receiving the sedatives, benzodiazepine and propofol doses were increa

87 t score, and median daily dose of analgesics/sedatives ( beta^ = 0.671, p = 0.010).

88 is able to detect the presence of two common sedatives, bromazolam (0.32-36% w/w) and xylazine (0.15-

89 re widely used as anti-pruritics and central sedatives, but demonstrate only modest anti-inflammatory

90 preexisting cognitive impairment, and use of sedatives; but to date, the relationship between race an

91 received significantly higher doses of both sedatives compared with older patients to achieve compar

92 rcome with sleeping medication (zolpidem) or sedatives (dexmedetomidine; Dex).

93 ows that subjects rendered unresponsive with sedatives do not exhibit a stereotypic 'unconscious' res

94 itoring of anesthetic depth for titration of sedatives, en route to avoiding emetogenic and hyperalge

95 Sedatives, even given intermittently, substantially redu

96 Intravenous sedatives examined included benzodiazepines (midazolam a

97 estational age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), mechanical ve

98 %) were reported as the most frequently used sedatives; fentanyl (44%) and morphine (20%) the most fr

99 onist medications are the most commonly used sedatives for intensive care unit (ICU) patients, yet pr

100 Surges in demand for sedatives for mechanical ventilation during the COVID-19

101 dorsing the use of high doses of opioids and sedatives for pain control, regardless of the risk that

102 ologists and other specialists administering sedatives for their own or others' procedures.

103 ng the COVID-19 pandemic caused shortages of sedatives globally.

104 sed, and among 54 patients on opioids and/or sedatives >= 72 hours, 9 (17%) had an IWS policy/protoco

105 ration following exposure to anesthetics and sedatives has been clearly established in developing ani

106 Some anesthetics and sedatives have been shown to cause neurotoxic effects in

107 (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), antidepressa

108 (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI drugs (HR

109 of clinical agents, including anaesthetics, sedatives, hypnotics and antidepressants(1-3).

110 Particularly addressing the fields of sedatives, hypnotics and neuromuscular blockers, however

111 Patients may use sedatives, hypnotics, or alcohol in an effort to interru

112 al ventilation (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in neonates

113 uideline-recommended treatment, or hypnotics/sedatives improves heart- or brain-related outcomes.

114 up, these drugs were administered as primary sedatives in 60%, 12%, and 20% of the patients, respecti

115 plications related to the use of opioids and sedatives in an elderly population.

116 anically ventilated adult patients receiving sedatives in an ICU setting were used to develop and tes

117 Differences exist between these sedatives in arousability, immunity, and inflammation.

118 e drug that effectively lowered the need for sedatives in critically ill patients managed in the COVI

119 xmedetomidine and propofol are commonly used sedatives in neurocritical care as they allow for freque

120 evidence for patterns of use of opioids and sedatives in palliative care and examine whether the doc

121 ssociated with increased dose or duration of sedatives in patients with acute lung injury.

122 information and the wide spread use of both sedatives in routine practice the pharmacovigilance plan

123 patients received parenteral opioids, and/or sedatives in the previous 24 hours.

124 attenuated TLR7 activation among intravenous sedatives in the reporter assay.

125 reatment, or increases in dose of opioids or sedatives, is associated with precipitation of death.

126 limited knowledge of the mechanisms by which sedatives mediate their effects on brain-wide networks.

127 ostoperative management strategy that avoids sedatives, muscle relaxants, and physical restraints, an

128 as no higher rate of infection or the use of sedatives, narcotics, or antibiotics in the catheter gro

129 whether propranolol could reduce the dose of sedatives needed in mechanically ventilated patients.

130 rtant anatomic site mediating the effects of sedatives on naturally occurring sleep.

131 The effects of sedatives on portal pressure measurements have not yet b

132 m, coma, sepsis, mechanical ventilation, and sedatives/opiates.

133 dence (marijuana, cocaine, other stimulants, sedatives, opioids), or habitual smoking at first interv

134 The use of sedatives, opioids, and neuromuscular blocking agents (N

135 her positive end-expiratory pressure (PEEP), sedatives, opioids, and NMBAs are used in a higher propo

136 ively collected data regarding the impact of sedatives, opioids, and NMBAs in ALI/ARDS patients on du

137 antidepressants that are toxic in overdose, sedatives, opioids, and potentially lethal combinations.

138 se of other drugs (ie, cannabis, stimulants, sedatives, opioids, inhalants, or performance enhancers)

139 e percentage of study days patients received sedatives, opioids, or neuromuscular blockade.

140 lness, comorbid conditions, coma, and use of sedatives or analgesic medications), delirium was indepe

141 Clinicians frequently escalate the dose of sedatives or analgesics to dying patients as life-sustai

142 e inhibitors (aHR, 2.68; 95% CI, 1.54-4.64), sedatives or hypnotics (aHR, 2.70; 95% CI, 1.40-5.19), o

143 three drug classes (opioids, stimulants, and sedatives or tranquilisers) from adolescence into adulth

144 (OR, 1.34; 95% CI, 1.12-1.60), hypnotics and sedatives (OR, 1.21; 95% CI, 1.02-1.43), or antidepressa

145 [95% CI, 1.27-1.81), lifetime consumption of sedatives (OR, 2.26 [95% CI, 1.65-3.14]), participating

146 prescribed use of anxiolytics, hypnotics and sedatives, or antidepressants was associated with a high

147 , antidepressants, anxiolytics, hypnotics or sedatives, or antipsychotics or prescriptions of any of

148 The use of analgesics, sedatives, or extubation did not significantly influence

149 akes/outputs, requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage

150 ids, stimulants, alcohol, cannabis, cocaine, sedatives, or other substances and/or (2) PD, including

151 majority of adults using prescribed opioids, sedatives, or tranquilizers (568 participants [52.2%]; 9

152 e aware that many adults prescribed opioids, sedatives, or tranquilizers had multiple SUD symptoms du

153 Female gender (p = .019), the absence of sedatives (p = .009), and lower Acute Physiology and Chr

154 ver, this may be reduced during sleep and by sedatives, potent analgesics, and volatile anesthetics.

155 cost-effectiveness of the most commonly used sedatives prescribed for mechanically ventilated critica

156 neurodegenerative pathology, side effects of sedatives, renal dysfunction and latent virus reactivati

157 CI, 1.30-1.50] in children for hypnotics and sedatives; RR, 1.38 [95% CI, 1.29-1.47] in adolescents a

158 for marijuana to 0.63 (CI, 0.47 to 0.78) for sedatives; specificity was 0.93 or higher.

159 atients, due to a combination of illness and sedatives, spend a considerable amount of time in a coma

160 endence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates was assessed at perso

161 cannabis, hallucinogens, inhalants, opioids, sedatives, stimulants, and other substances).

162 nt probands for cocaine, marijuana, opiates, sedatives, stimulants, and tobacco.

163 se, and abuse of and dependence on cannabis, sedatives, stimulants, cocaine, opiates, and hallucinoge

164 actor that underlies the abuse of marijuana, sedatives, stimulants, heroin or opiates, and psychedeli

165 Abrupt discontinuation of use of sedatives such as benzodiazepines and ethanol can also p

166 als, all currently available anesthetics and sedatives that have been studied, such as ketamine, mida

167 se results could help with the design of new sedatives that induce a more natural sleep.

168 ved regarding the days free of analgesics or sedatives, the duration of night sleep, and the occurren

169 tibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription.

170 e usual-care group and required supplemental sedatives to achieve the prescribed level of sedation.

171 no observed adverse effect of the additional sedatives used.

172 oportion of patients weaned from opioids and sedatives using an institutional policy/protocol on the

173 However, like all sedatives, volatile agents are capable of deeply sedatin

174 The use of analgesics and sedatives was assessed daily.

175 Sedatives were administered in 85% of 18,050 four-hour i

176 Sedatives were also associated with increased time to ac

177 ety symptoms associated with lifetime use of sedatives were higher among adolescents (OR, 6.54 [95% C

178 motherapy, inotropes, vasoactive agents, and sedatives were the most frequently proposed needed thera

179 Sedated patients had received more sedatives, whereas doses of morphine and antipsychotics

180 Critically ill patients often receive sedatives, which may delay liberation from mechanical ve

181 anolol may help preserve limited supplies of sedatives while achieving target sedation.

182 Evaluation II score and cumulative doses of sedatives while comatose.

183 nned to compare midazolam and clonidine, two sedatives widely used within PICUs neither of which bein

184 aneous awakening trials (ie, interruption of sedatives) with daily spontaneous breathing trials resul

185 ning trials (SATs)-ie, daily interruption of sedatives-with spontaneous breathing trials (SBTs).